Medicare Exposure at Risk: 2026-2030
0 drugs losing exclusivity ($0 in Medicare Part D spending)
Note: Shows Medicare Part D spending only, not total drug revenue
Medicare Part D as a Proxy for Revenue Impact
This analysis uses Medicare Part D spending as an approximate way to visualize patent cliff impact. It's not total drug revenue, but serves as a useful proxy for understanding the magnitude of losses:
- Why it works as a proxy: Medicare Part D (~30% of US drug spending) shows the same decline patterns as total revenue after generic entry. When Lyrica lost exclusivity, Part D spending dropped 97% — and total revenue followed the same trajectory.
- Public and verifiable: CMS publishes exact dollar amounts per drug annually. Company 10-K/10-Q filings also report revenue by drug — we could extend this analysis with that data.
- Conservative estimate: For drugs with elderly patient populations (cardiovascular, diabetes, oncology), Medicare is often the largest single payer — so Part D may actually represent 40-50% of US sales.
For precise total revenue: Company SEC 10-K filings report product-level sales. This dashboard is an academic exercise using publicly available data to illustrate patent cliff dynamics.
Data through 2024 — Pre-cliff baseline for most drugs
CMS Medicare Part D data is available through 2024. For drugs with patents expiring in 2026+, the charts show pre-cliff spending — the actual decline will appear in future data releases after generic entry.
Drugs already showing decline (e.g., Spiriva Handihaler down 62%) have either: (1) generics entered via settlement, or (2) patients switching to newer formulations.
Understanding Drug Protection: Patents vs Exclusivity
Drugs are protected by two separate legal mechanisms. A generic can only launch when BOTH allow it.
Patents (USPTO)
- What: Intellectual property right from Patent Office
- Duration: 20 years from filing date
- Granted by: USPTO (not FDA)
- Can be challenged: Yes - Paragraph IV litigation
- Compound/substance - the molecule itself
Example: Humira's adalimumab molecule patent expired 2023, enabling biosimilars
- Formulation - how it's made/delivered
Example: Lantus pen device patents extended protection beyond insulin patent
- Method of use - specific indications
Example: Ozempic has compound patent expiring 2026, but another compound patent (with PTE) extends to 2031, plus use patents to 2038
Exclusivity (FDA)
- What: Marketing protection as regulatory incentive
- Duration: Varies by type (see below)
- Granted by: FDA (not Patent Office)
- Cannot be challenged: Automatic, runs its course
| Code | Type | Duration | Example |
|---|---|---|---|
| NCE | New Chemical Entity | 5 years | Ozempic (2022-2027) |
| NEW | New Indication | 3 years | Keytruda new cancer types |
| ODE | Orphan Drug | 7 years | Revlimid for myeloma |
| PED | Pediatric | +6 months | Added to existing patents |
Medicare Part D Spending by Patent Expiry Year
Historical Evidence: What Actually Happens
Unlike analyst forecasts, this data shows actual Medicare Part D spending before and after patent expiry.
Note: Medicare Part D spending is not total drug revenue. It represents only one payer segment (~30% of US drug market). Total revenue includes commercial insurance, Medicare Part B, Medicaid, cash pay, and international sales. The same analysis can be performed with total revenue data from company SEC filings.
How we calculated these numbers (click to expand)
- Peak: $2.03B (2019)
- Latest: $0.06B (2024)
- Decline: ($2.03B - $0.06B) / $2.03B = 97%
- Small molecules: 85-97% decline within 2-5 years
- Complex generics: 60-70% decline (harder to copy)
- Biologics: 2-40% decline in first years (biosimilar pathway slower)
2026 Patent Cliff 0 drugs | $0 Part D spending
No drugs with significant Medicare spending (>$100M) expiring in 2026.
2027 Patent Cliff 0 drugs | $0 Part D spending
No drugs with significant Medicare spending (>$100M) expiring in 2027.
2028 Patent Cliff 0 drugs | $0 Part D spending
No drugs with significant Medicare spending (>$100M) expiring in 2028.
2029 Patent Cliff 0 drugs | $0 Part D spending
No drugs with significant Medicare spending (>$100M) expiring in 2029.
2030 Patent Cliff 0 drugs | $0 Part D spending
No drugs with significant Medicare spending (>$100M) expiring in 2030.
Important: Patent Litigation Settlements
The dates shown are from the FDA Orange Book and reflect official patent/exclusivity expiration dates. However, many blockbuster drugs have litigation settlement agreements that allow generic entry before patent expiry.
Settlement terms are often confidential and not available in structured databases. For investment decisions, verify actual generic launch dates with SEC filings ( 8-K filings ) and news sources.
Methodology & Limitations
Data Sources
- Patent/Exclusivity: FDA Orange Book (drug-patents.json)
- Spending: CMS Medicare Part D (2023) (Part D only, not total revenue)
How Expiry Dates Are Calculated
Uses LATEST of (patent expiry, exclusivity expiry) as effective protection end date. This is when generic/biosimilar competition can legally begin.
Important Limitations
- Medicare Part D spending is NOT total drug revenue - it represents ~30% of US drug market. Total revenue includes commercial insurance, Medicare Part B, Medicaid, cash pay, and international sales.
- Drugs may have multiple patents - we use the LATEST expiry date
- Method-of-use patents may be designed around by generics with carved-out labels
- Patent litigation and settlements can delay or accelerate generic entry
- Biologics follow biosimilar pathway (typically slower erosion than small molecules)
- Does not account for 180-day exclusivity for first generic filer
Our Approach: Unlike analyst forecasts that rely on proprietary models, our predictions are grounded in actual historical Medicare spending data. We show you what really happened to drugs that lost exclusivity, then apply those patterns to predict future outcomes. This is public data you can verify.